Final CESARE trial results show continued clinical and survival benefit.
D000081:Acetamides / Q000008:administration & dosage; D000098:Acetophenones / Q000008:administration & dosage; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D018849:Controlled Clinical Trials as Topic; D016049:Didanosine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D015996:Survival Rate; D016047:Zalcitabine / Q000008:administration & dosage; D015215:Zidovudine / Q000008:administration & dosage
D000081:Acetamides; D000098:Acetophenones; D019380:Anti-HIV Agents; D000998:Antiviral Agents; D019259:Lamivudine; C080073:loviride; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine